Serum bilirubin may serve as a marker for increased heme oxygenase activity and inducibility in tissues - A rationale for the versatile health protection associated with elevated plasma bilirubin

Medical Hypotheses

Volumn 81, Issue 4, 2013, Pages 607-610

  McCarty, Mark F ^a  

^a NutriGuard Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; BILIVERDIN; CARBON MONOXIDE; GLUCURONOSYLTRANSFERASE 1A1; HEME OXYGENASE; HEME OXYGENASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANTIOXIDANT ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY MASS; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEEDBACK SYSTEM; GILBERT DISEASE; HEALTH PROMOTION; HOMOZYGOSITY; HUMAN; ISCHEMIC HEART DISEASE; LIVER FUNCTION; NONHUMAN; OXIDATIVE STRESS; PROPHYLAXIS; PROTEIN EXPRESSION; RISK ASSESSMENT; TUMOR MICROENVIRONMENT;

CYANOBACTERIA; RATTUS NORVEGICUS;

ANIMALS; BILIRUBIN; BIOLOGICAL MARKERS; GILBERT DISEASE; GLUCURONOSYLTRANSFERASE; HEME OXYGENASE (DECYCLIZING); HUMANS; RATS; VASCULAR DISEASES;

EID: 84883760615     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.07.013     Document Type: Article

References (70)

1. Schwertner H.A., Vitek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis 2008, 198(1):1-11.
2. Horsfall L.J., Nazareth I., Petersen I. Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation 2012, 126(22):2556-2564.
3. Horsfall L.J., Rait G., Walters K., et al. Serum bilirubin and risk of respiratory disease and death. JAMA 2011, 305(7):691-697.
4. Inoguchi T., Sasaki S., Kobayashi K., Takayanagi R., Yamada T. Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. JAMA 2007, 298(12):1398-1400.
5. McCarty M.F. "Iatrogenic Gilbert syndrome"-a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses 2007, 69(5):974-994.
6. Chan K.H., O'Connell R.L., Sullivan D.R., et al. Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (FIELD) study. Diabetologia 2013, 56(4):724-736.
7. Cheriyath P., Gorrepati V.S., Peters I., et al. High total bilirubin as a protective factor for diabetes mellitus: an analysis of NHANES data from 1. J Clin Med Res 2010, 2(5):201-206.
8. Fischman D., Valluri A., Gorrepati V.S., Murphy M.E., Peters I., Cheriyath P. Bilirubin as a protective factor for rheumatoid arthritis: an NHANES study of 2. J Clin Med Res 2010, 2(6):256-260.
9. Horsfall L.J., Nazareth I., Pereira S.P., Petersen I. Gilbert's syndrome and the risk of death: a population-based cohort study. J Gastroenterol Hepatol 2013.
10. Rauchschwalbe S.K., Zuhlsdorf M.T., Schuhly U., Kuhlmann J. Predicting the risk of sporadic elevated bilirubin levels and diagnosing Gilbert's syndrome by genotyping UGT1A1*28 promoter polymorphism. Int J Clin Pharmacol Ther 2002, 40(6):233-240.
11. Gil J., Sasiadek M.M. Gilbert syndrome: the UGT1A1*28 promoter polymorphism as a biomarker of multifactorial diseases and drug metabolism. Biomark Med 2012, 6(2):223-230.
12. Stocker R., Glazer A.N., Ames B.N. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci USA 1987, 84(16):5918-5922.
13. Bulmer A.C., Blanchfield J.T., Toth I., Fassett R.G., Coombes J.S. Improved resistance to serum oxidation in Gilbert's syndrome: a mechanism for cardiovascular protection. Atherosclerosis 2008, 199(2):390-396.
14. Vitek L., Ostrow J.D. Bilirubin chemistry and metabolism; harmful and protective aspects. Curr Pharm Des 2009, 15(25):2869-2883.
15. Sedlak T.W., Snyder S.H. Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics 2004, 113(6):1776-1782.
16. Maghzal G.J., Leck M.C., Collinson E., Li C., Stocker R. Limited role for the bilirubin-biliverdin redox amplification cycle in the cellular antioxidant protection by biliverdin reductase. J Biol Chem 2009, 284(43):29251-29259.
17. Lanone S., Bloc S., Foresti R., et al. Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J 2005, 19(13):1890-1892.
18. Jiang F., Roberts S.J., Datla S., Dusting G.J. NO modulates NADPH oxidase function via heme oxygenase-1 in human endothelial cells. Hypertension 2006, 48(5):950-957.
19. Matsumoto H., Ishikawa K., Itabe H., Maruyama Y. Carbon monoxide and bilirubin from heme oxygenase-1 suppresses reactive oxygen species generation and plasminogen activator inhibitor-1 induction. Mol Cell Biochem 2006, 291(1-2):21-28.
20. Datla S.R., Dusting G.J., Mori T.A., Taylor C.J., Croft K.D., Jiang F. Induction of heme oxygenase-1 in vivo suppresses NADPH oxidase derived oxidative stress. Hypertension 2007, 50(4):636-642.
21. Basuroy S., Bhattacharya S., Leffler C.W., Parfenova H. Nox4 NADPH oxidase mediates oxidative stress and apoptosis caused by TNF-alpha in cerebral vascular endothelial cells. Am J Physiol Cell Physiol 2009, 296(3):C422-C432.
22. Wang H., Lee S.S., Dell'Agnello C., et al. Bilirubin can induce tolerance to islet allografts. Endocrinology 2006, 147(2):762-768.
23. Rocuts F., Zhang X., Yan J., et al. Bilirubin promotes de novo generation of T regulatory cells. Cell Transplant 2010, 19(4):443-451.
24. McCarty M.F. Clinical potential of phycocyanobilin for induction of T regulatory cells in the management of inflammatory disorders. Med Hypotheses 2011, 77(6):1031-1033.
25. Stender S., Frikke-Schmidt R., Nordestgaard B.G., Grande P., Tybjaerg-Hansen A. Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a meta-analysis. J Intern Med 2013, 273(1):59-68.
26. McArdle P.F., Whitcomb B.W., Tanner K., Mitchell B.D., Shuldiner A.R., Parsa A. Association between bilirubin and cardiovascular disease risk factors: using Mendelian randomization to assess causal inference. BMC Cardiovasc Disord 2012, 12:16.
27. Bach F.H. Heme oxygenase-1 as a protective gene. Wien Klin Wochenschr 2002, 114(Suppl. 4):1-3.
28. Zhang J., Ohta T., Maruyama A., et al. BRG1 interacts with Nrf2 to selectively mediate HO-1 induction in response to oxidative stress. Mol Cell Biol 2006, 26(21):7942-7952.
29. Exner M., Minar E., Wagner O., Schillinger M. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med 2004, 37(8):1097-1104.
30. Exner M., Schillinger M., Minar E., et al. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther 2001, 8(5):433-440.
31. Chen Y.H., Lin S.J., Lin M.W., et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 2002, 111(1):1-8.
32. Schillinger M., Exner M., Mlekusch W., et al. Heme oxygenase-1 gene promoter polymorphism is associated with abdominal aortic aneurysm. Thromb Res 2002, 106(2):131-136.
33. Kaneda H., Ohno M., Taguchi J., et al. Heme oxygenase-1 gene promoter polymorphism is associated with coronary artery disease in Japanese patients with coronary risk factors. Arterioscler Thromb Vasc Biol 2002, 22(10):1680-1685.
34. Chen Y.H., Chau L.Y., Lin M.W., et al. Heme oxygenase-1 gene promotor microsatellite polymorphism is associated with angiographic restenosis after coronary stenting. Eur Heart J 2004, 25(1):39-47.
35. Schillinger M., Exner M., Minar E., et al. Heme oxygenase-1 genotype and restenosis after balloon angioplasty: a novel vascular protective factor. J Am Coll Cardiol 2004, 43(6):950-957.
36. Funk M., Endler G., Schillinger M., et al. The effect of a promoter polymorphism in the heme oxygenase-1 gene on the risk of ischaemic cerebrovascular events: the influence of other vascular risk factors. Thromb Res 2004, 113(3-4):217-223.
37. Gulesserian T., Wenzel C., Endler G., et al. Clinical restenosis after coronary stent implantation is associated with the heme oxygenase-1 gene promoter polymorphism and the heme oxygenase-1 +99G/C variant. Clin Chem 2005, 51(9):1661-1665.
38. Dick P., Schillinger M., Minar E., et al. Haem oxygenase-1 genotype and cardiovascular adverse events in patients with peripheral artery disease. Eur J Clin Invest 2005, 35(12):731-737.
39. Morgan L., Hawe E., Palmen J., Montgomery H., Humphries S.E., Kitchen N. Polymorphism of the heme oxygenase-1 gene and cerebral aneurysms. Br J Neurosurg 2005, 19(4):317-321.
40. Chen Y.H., Chau L.Y., Chen J.W., Lin S.J. Serum bilirubin and ferritin levels link heme oxygenase-1 gene promoter polymorphism and susceptibility to coronary artery disease in diabetic patients. Diabetes Care 2008, 31(8):1615-1620.
41. Bai C.H., Chen J.R., Chiu H.C., Chou C.C., Chau L.Y., Pan W.H. Shorter GT repeat polymorphism in the heme oxygenase-1 gene promoter has protective effect on ischemic stroke in dyslipidemia patients. J Biomed Sci 2010, 17:12.
42. Wu M.M., Chiou H.Y., Chen C.L., et al. GT-repeat polymorphism in the heme oxygenase-1 gene promoter is associated with cardiovascular mortality risk in an arsenic-exposed population in northeastern Taiwan. Toxicol Appl Pharmacol 2010, 248(3):226-233.
43. Wu M.M., Chiou H.Y., Lee T.C., et al. GT-repeat polymorphism in the heme oxygenase-1 gene promoter and the risk of carotid atherosclerosis related to arsenic exposure. J Biomed Sci 2010, 17:70.
44. Wu M.M., Chiou H.Y., Chen C.L., et al. Association of heme oxygenase-1 GT-repeat polymorphism with blood pressure phenotypes and its relevance to future cardiovascular mortality risk: an observation based on arsenic-exposed individuals. Atherosclerosis 2011, 219(2):704-708.
45. Chen M., Zhou L., Ding H., et al. Short (GT) (n) repeats in heme oxygenase-1 gene promoter are associated with lower risk of coronary heart disease in subjects with high levels of oxidative stress. Cell Stress Chaperones 2012, 17(3):329-338.
46. D'Silva S., Borse V., Colah R.B., Ghosh K., Mukherjee M.B. Association of (GT)n repeats promoter polymorphism of heme oxygenase-1 gene with serum bilirubin levels in healthy Indian adults. Genet Test Mol Biomarkers 2011, 15(4):215-218.
47. Jung N.H., Kim H.P., Kim B.R., et al. Evidence for heme oxygenase-1 association with caveolin-1 and -2 in mouse mesangial cells. IUBMB Life 2003, 55(9):525-532.
48. Kim H.P., Wang X., Galbiati F., Ryter S.W., Choi A.M. Caveolae compartmentalization of heme oxygenase-1 in endothelial cells. FASEB J 2004, 18(10):1080-1089.
49. Wang X.M., Kim H.P., Nakahira K., Ryter S.W., Choi A.M. The heme oxygenase-1/carbon monoxide pathway suppresses TLR4 signaling by regulating the interaction of TLR4 with caveolin-1. J Immunol 2009, 182(6):3809-3818.
50. Zheng Y., Morris A., Sunkara M., Layne J., Toborek M., Hennig B. Epigallocatechin-gallate stimulates NF-E2-related factor and heme oxygenase-1 via caveolin-1 displacement. J Nutr Biochem 2012, 23(2):163-168.
51. Yang B., Rizzo V. TNF-alpha potentiates protein-tyrosine nitration through activation of NADPH oxidase and eNOS localized in membrane rafts and caveolae of bovine aortic endothelial cells. Am J Physiol Heart Circ Physiol 2007, 292(2):H954-H962.
52. Ushio-Fukai M. Compartmentalization of redox signaling through NADPH oxidase-derived ROS. Antioxid Redox Signal 2009, 11(6):1289-1299.
53. Zhang Y., Peng F., Gao B., Ingram A.J., Krepinsky J.C. Mechanical strain-induced RhoA activation requires NADPH oxidase-mediated ROS generation in caveolae. Antioxid Redox Signal 2010, 13(7):959-973.
54. Lobysheva I., Rath G., Sekkali B., et al. Moderate caveolin-1 downregulation prevents NADPH oxidase-dependent endothelial nitric oxide synthase uncoupling by angiotensin II in endothelial cells. Arterioscler Thromb Vasc Biol 2011, 31(9):2098-2105.
55. Zhang Y., Peng F., Gao B., Ingram A.J., Krepinsky J.C. High glucose-induced RhoA activation requires caveolae and PKCbeta1-mediated ROS generation. Am J Physiol Renal Physiol 2012, 302(1):F159-F172.
56. Ollinger R., Bilban M., Erat A., et al. Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation. Circulation 2005, 112(7):1030-1039.
57. Nath K.A., d'Uscio L.V., Juncos J.P., et al. An analysis of the DOCA-salt model of hypertension in HO-1-/- mice and the Gunn rat. Am J Physiol Heart Circ Physiol 2007, 293(1):H333-H342.
58. Pflueger A., Croatt A.J., Peterson T.E., et al. The hyperbilirubinemic Gunn rat is resistant to the pressor effects of angiotensin II. Am J Physiol Renal Physiol 2005, 288(3):F552-F558.
59. Fujii M., Inoguchi T., Sasaki S., et al. Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD(P)H oxidase. Kidney Int 2010, 78(9):905-919.
60. Dekker D., Dorresteijn M.J., Pijnenburg M., et al. The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2011, 31(2):458-463.
61. Andersson C., Weeke P., Fosbol E.L., et al. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the sibutramine cardiovascular outcome trial. Metabolism 2009, 58(8):1109-1115.
62. Jo J., Kimm H., Yun J.E., Lee K.J., Jee S.H. Cigarette smoking and serum bilirubin subtypes in healthy Korean men: the Korea Medical Institute study. J Prev Med Public Health 2012, 45(2):105-112.
63. Nakao A., Neto J.S., Kanno S., et al. Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both. Am J Transplant 2005, 5(2):282-291.
64. Berberat P.O., Rahim Y.I., Yamashita K., et al. Heme oxygenase-1-generated biliverdin ameliorates experimental murine colitis. Inflamm Bowel Dis 2005, 11(4):350-359.
65. Ollinger R., Yamashita K., Bilban M., et al. Bilirubin and biliverdin treatment of atherosclerotic diseases. Cell Cycle 2007, 6(1):39-43.
66. Ollinger R., Wang H., Yamashita K., et al. Therapeutic applications of bilirubin and biliverdin in transplantation. Antioxid Redox Signal 2007, 9(12):2175-2185.
67. Bonelli M., Savitskaya A., Steiner C.W., et al. Heme oxygenase-1 end-products carbon monoxide and biliverdin ameliorate murine collagen induced arthritis. Clin Exp Rheumatol 2012, 30(1):73-78.
68. Ikeda N., Inoguchi T., Sonoda N., et al. Biliverdin protects against the deterioration of glucose tolerance in db/db mice. Diabetologia 2011, 54(8):2183-2191.
69. Zheng J., Inoguchi T., Sasaki S., et al. Phycocyanin and phycocyanobilin from Spirulina platensis protect against diabetic nephropathy by inhibiting oxidative stress. Am J Physiol Regul Integr Comp Physiol 2013, 304(2):R110-R120.
70. McCarty M.F. Clinical potential of Spirulina as a source of phycocyanobilin. J Med Food 2007, 10(4):566-570.